MA47743A - Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations - Google Patents

Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Info

Publication number
MA47743A
MA47743A MA047743A MA47743A MA47743A MA 47743 A MA47743 A MA 47743A MA 047743 A MA047743 A MA 047743A MA 47743 A MA47743 A MA 47743A MA 47743 A MA47743 A MA 47743A
Authority
MA
Morocco
Prior art keywords
beta
solid forms
compositions including
lactamase inhibitor
combination compositions
Prior art date
Application number
MA047743A
Other languages
English (en)
Inventor
Jean-Baptiste Arlin
Gerald Brenner
Christopher J Burns
Casares Ana Fernandez
Timothy Henkel
Daniel Mcgarry
Daniel C Pevear
Lawrence Rosen
Luigi Xerri
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of MA47743A publication Critical patent/MA47743A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
MA047743A 2017-03-06 2018-03-05 Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations MA47743A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762467752P 2017-03-06 2017-03-06
US201762467750P 2017-03-06 2017-03-06
US201762564989P 2017-09-28 2017-09-28
US201762564990P 2017-09-28 2017-09-28

Publications (1)

Publication Number Publication Date
MA47743A true MA47743A (fr) 2020-01-15

Family

ID=63448038

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047743A MA47743A (fr) 2017-03-06 2018-03-05 Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Country Status (14)

Country Link
US (3) US11091505B2 (fr)
EP (1) EP3592362A4 (fr)
JP (2) JP2020510661A (fr)
KR (1) KR102603489B1 (fr)
CN (2) CN117398398A (fr)
AU (1) AU2018230991B2 (fr)
BR (1) BR112019018447A2 (fr)
CA (1) CA3055253A1 (fr)
IL (2) IL301591A (fr)
MA (1) MA47743A (fr)
MY (1) MY196966A (fr)
PH (1) PH12019502037A1 (fr)
SG (1) SG11201908181XA (fr)
WO (1) WO2018165048A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089365A1 (fr) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Inhibiteurs de bêta-lactamase
WO2014110442A1 (fr) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2874579T3 (es) 2014-06-11 2021-11-05 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (fr) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
WO2018027062A1 (fr) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Composés contenant du bore
AU2018230991B2 (en) 2017-03-06 2023-07-13 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218154A1 (fr) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Inhibiteurs protéiques de liaison à la pénicilline
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
CN113015532B (zh) 2018-09-12 2024-03-15 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021454A (en) 1911-01-23 1912-03-26 Thomas Ernest Davis Serving-table.
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
ES2457593T3 (es) 2004-03-30 2014-04-28 Millennium Pharmaceuticals, Inc. Síntesis de bortezomib
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β-内酰胺酶抑制剂的药物组合物
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR069310A1 (es) 2007-11-13 2010-01-13 Protez Pharmaceuticals Inc Inhibidores de beta- lactamasa
UA101966C2 (en) 2008-01-18 2013-05-27 Мерк Шарп Енд Доме Корп. Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
ES2789177T3 (es) 2010-08-10 2020-10-26 Melinta Therapeutics Inc Derivados de éster del ácido borónico cíclicos, procedimiento para la preparación y usos terapéuticos de los mismos
EP2768503A1 (fr) * 2011-07-26 2014-08-27 Wockhardt Limited Compositions pharmaceutiques comprenant un antibiotique bêta-lactame, du sulbactam et un inhibiteur de bêta-lactamase
WO2013053372A1 (fr) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Inhibiteurs de type acide boronique de bêta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP5798495B2 (ja) 2012-01-13 2015-10-21 住友理工株式会社 配線体接続構造体
EP2814483A2 (fr) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Méthodes de traitement d'infections bactériennes
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
WO2014089365A1 (fr) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Inhibiteurs de bêta-lactamase
CA2894891A1 (fr) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Derives d'acide boronique et leurs utilisations therapeutiques
AU2014204046B2 (en) 2013-01-04 2017-02-23 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014110442A1 (fr) 2013-01-10 2014-07-17 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (fr) 2014-04-11 2015-10-15 The Texas A&M University System Nouveaux inhibiteurs de la new delhi métallo-bêta-lactamase (ndm-1)
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
ES2874579T3 (es) 2014-06-11 2021-11-05 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
KR101935186B1 (ko) 2014-09-04 2019-01-03 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류를 함유하는 제제
ES2761778T3 (es) 2014-12-19 2020-05-21 Rempex Pharmaceuticals Inc Aparato y proceso de flujo continuo para la producción de derivados de ácido borónico
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
WO2018027062A1 (fr) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Composés contenant du bore
AU2018230991B2 (en) 2017-03-06 2023-07-13 VenatoRx Pharmaceuticals, Inc. Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3802551A4 (fr) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
CN113015532B (zh) 2018-09-12 2024-03-15 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物
MA54319A (fr) 2018-11-29 2021-10-06 Venatorx Pharmaceuticals Inc Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Also Published As

Publication number Publication date
EP3592362A1 (fr) 2020-01-15
IL268981A (en) 2019-10-31
CN117398398A (zh) 2024-01-16
CA3055253A1 (fr) 2018-09-13
KR102603489B1 (ko) 2023-11-16
IL301591A (en) 2023-05-01
JP2023061946A (ja) 2023-05-02
EP3592362A4 (fr) 2020-09-02
WO2018165048A1 (fr) 2018-09-13
MY196966A (en) 2023-05-15
BR112019018447A2 (pt) 2020-04-14
SG11201908181XA (en) 2019-10-30
US11091505B2 (en) 2021-08-17
AU2018230991A1 (en) 2019-09-19
CN110678186A (zh) 2020-01-10
PH12019502037A1 (en) 2020-03-09
IL268981B2 (en) 2023-09-01
US20200010485A1 (en) 2020-01-09
IL268981B1 (en) 2023-05-01
JP2020510661A (ja) 2020-04-09
AU2018230991B2 (en) 2023-07-13
US11820784B2 (en) 2023-11-21
KR20190117790A (ko) 2019-10-16
US20240101580A1 (en) 2024-03-28
US20220002322A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MA47743A (fr) Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
MA54319A (fr) Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
MA53243A (fr) Compositions comprenant une combinaison de ipilimumab et nivolumab
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA52483A (fr) Dérivés de gip et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA55565A (fr) Agents de dégradation de stat et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA51204A (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46203A (fr) Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
MA43650A (fr) Formulations/compositions comprenant un inhibiteur de btk
MA52365A (fr) Composés et leurs utilisations
MA50413A (fr) Dérivés de benzimidazole et leurs utilisations
MA49133A (fr) Anticorps agonistes anti-btla et leurs utilisations
MA41634A (fr) Formulation à base de combinaison de tésofensine et de bêta-bloquant
MA49837A (fr) Compositions pharmaceutiques